Key Takeaways:
CSPC Pharmaceutical Group (01093.HK) won Chinese regulatory approval to begin clinical trials of SYS6063, the first mRNA-LNP-based dual-target CAR-T therapy, for relapsed and refractory systemic lupus erythematosus.
"The approval marks a significant step in our cell therapy strategy," the company said in a filing. The therapy uses mRNA-LNP technology to express chimeric antigen receptors targeting both CD19 and BCMA, enabling precise elimination of disease-causing B cells and plasma cells.
The National Medical Products Administration cleared the investigational new drug application for SYS6063, which demonstrated strong preclinical safety and efficacy. Beyond lupus, CSPC plans to study the therapy in other B-cell and plasma cell-mediated autoimmune diseases including myasthenia gravis, rheumatoid arthritis, and ANCA-associated vasculitis. The company also expects to expand into hematologic malignancies such as relapsed or refractory multiple myeloma and B-cell lymphoma.
Shares of CSPC fell 3.4% to close at an undisclosed level on Tuesday, with short selling reaching HK$217.5 million, or 24.2% of total turnover. CLSA reiterated its Buy rating and "Conviction List Outperform" designation with a HK$19 price target after the company's first-quarter 2026 earnings beat estimates.
The approval positions CSPC as a pioneer in next-generation cell therapy in China, with the mRNA-LNP platform potentially enabling in vivo CAR-T generation in future programs. Investors will watch for initial safety and efficacy data from the lupus trial, which could validate the platform's broader applicability across autoimmune and oncology indications.
This article is for informational purposes only and does not constitute investment advice.
